Why Kratom Paradise Does Not Sell Synthetic 7-OH

Kratom Paradise does not sell synthetic 7-OH products. That is a deliberate brand decision, not an accident or a temporary catalog gap.

Why the human-effects profile matters to this policy

Kratom Paradise does not sell synthetic or enriched 7-OH products. People consume these products for strong opioid-like effects from a potent mu-opioid-receptor agonist at levels fundamentally different from ordinary kratom leaf. FDA warns that concentrated 7-OH can cause serious harm, and clinical literature describes tolerance, dependence, and withdrawal.

MIT tablets and extract powders are active mitragynine products, not risk-free alternatives. Mitragynine acts at human mu-opioid receptors, and regular use can involve unwanted effects or dependence. MIT belongs in a separate lane because it has a clearer compound identity and longer research history—not because concentrating it makes it harmless.

Anyone experiencing severe withdrawal, uncontrolled use, marked sedation, breathing problems, or other urgent symptoms should seek qualified medical care. A retail comparison cannot safely provide a 7-OH-to-MIT conversion or withdrawal protocol.

The brand is built around normal kratom and MIT

Kratom Paradise is built around clear product families: kratom powder, kratom capsules, bulk kratom capsules, MIT chewable tablets, MIT extract powder, and bulk MIT options. Those categories are enough to build a strong, modern kratom brand without chasing synthetic 7-OH.

The visual identity uses tropical color, sunrise energy, strong product photography, and memorable packaging. Every product still identifies its format and key options clearly.

Customers will find botanical kratom and clearly labeled MIT products, presented with distinct formats and no synthetic 7-OH category.

Synthetic 7-OH creates category confusion

Synthetic or elevated 7-OH products create confusion because they often borrow the language of kratom while behaving like a different market. They can look different, sell differently, and attract a different kind of regulatory attention. When those products are treated as if they are the same as botanical kratom, the entire category inherits the risk.

Kratom Paradise does not want customers, retailers, or regulators to guess what the brand sells. The store should make the difference obvious: botanical kratom products in one lane, MIT products in another, bulk options where appropriate, and no synthetic 7-OH.

Saying no can be pro-kratom

Some people treat every restriction as anti-kratom. Kratom Paradise sees it differently. Supporting a clean line between botanical kratom and synthetic 7-OH is one of the best ways to protect normal kratom products. The category does not get stronger by defending everything that borrows the kratom name.

A better future for kratom depends on adult-use product clarity, label discipline, state-by-state shipping controls, and a willingness to separate the plant from products that push far outside ordinary leaf chemistry. That is not fear. It is good category stewardship.

This position also gives customers a clearer shopping experience. They do not have to wonder whether a product is secretly part of the 7-OH trend. If it is on Kratom Paradise, it belongs to the normal kratom or MIT catalog.

What customers will find

Kratom Paradise offers kratom powder, kratom capsules, MIT chewable tablets, MIT extract powders, and clearly separated bulk quantities.

Each product identifies its format, relevant strength or fill language, flavor where applicable, and quantity or size. Synthetic 7-OH products are not offered.

DEA 7-OH announcement. HHS/FDA 7-OH recommendation. FDA 7-OH explainer.

A line that customers can understand

The policy is direct: Kratom Paradise sells botanical kratom products and clearly labeled MIT products. Kratom Paradise does not sell synthetic 7-OH.

A clear no also prevents category drift. Without a line, every new trend can pressure the catalog. A little more intensity here, a little more novelty there, and soon the store looks like the part of the market it was trying to separate from. Saying no to synthetic 7-OH protects the brand from that drift.

The policy is straightforward: Kratom Paradise focuses on botanical kratom, clearly identified MIT products, and a long-term market that separates those products from synthetic or enriched 7-OH.

A straightforward answer

The current Kratom Paradise catalog does not list 7-OH-centered products. MIT and 7-hydroxymitragynine are different label terms, and product-composition statements require product-specific evidence rather than a universal claim across the catalog.

Questions about a specific product label may be sent to support@kratomparadise.com.

How the current MIT evidence is described

The current catalog does not list 7-OH-centered products. Kratom Paradise has confirmed that its MIT chewable tablets use the 90% MIT-CH source concentrate associated with sample 141690. The source report lists 7-OH as ND under its stated method and limits.

That is a source-material statement. Kratom Paradise does not present the report as a finished-tablet test, a result for every production lot, a legal certification, a safety claim, or proof that MIT products are equivalent to 7-OH.

See the MIT document center and federal status tracker for the current scope and official-source links.